Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 7/20 | 0.62 |
| ▸ | MAP2K1 | Q02750 | 8/20 | 0.61 |
| ▸ | RAF1 | P04049 | 2/20 | 0.61 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.60 |
| ▸ | KDR | P35968 | 6/20 | 0.56 |
| ▸ | MET | P08581 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 3/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | LTK | P29376 | 1/20 | 0.55 |
| ▸ | TTK | P33981 | 1/20 | 0.55 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4447904 | 0.89 | MAP2K1 (0.72) | SRCMAP2K1RAF1MAPK3MAPK1 | |
| SCHEMBL4447835 | 0.87 | MAP2K1 (0.64) | SRCMAP2K1RAF1MAPK3MAPK1 | |
| SCHEMBL4558340 | 0.85 | MAP2K1 (0.71) | SRCMAP2K1RAF1MAPK3MAPK1 | |
| SCHEMBL6995929 | 0.85 | MAP2K1 (0.85) | SRCMAP2K1RAF1MAPK3MAPK1 | |
| SCHEMBL4557892 | 0.82 | MAP2K1 (0.73) | SRCMAP2K1FGFR2KDRMET | |
| SCHEMBL27731209 | 0.81 | KDR (0.62) | SRCKDRMETEGFRLCK | |
| SCHEMBL18828353 | 0.80 | SRC (0.57) | SRCMAP2K1FGFR2KDRMET | |
| SCHEMBL4557789 | 0.80 | MAP2K1 (0.73) | SRCMAP2K1FGFR2KDRMET | |
| SCHEMBL12308286 | 0.80 | EGFR (0.77) | SRCKDRMETEGFRLCK | |
| SCHEMBL4476247 | 0.79 | FGFR2 (0.92) | SRCMAP2K1RAF1MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009151910-A2 | COMBINATION PRODUCT OF RECEPTOR TYROSINE KINASE INHIBITOR AND FATTY ACID SYNTHASE INHIBITOR FOR TREATING CANCER | WYETH (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | FASN, FRS2, FGFR1 | SRC 9/4885MAP2K1 840/4885RAF1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.